MedTrace Logo

Voriconazole-Induced QT Interval Prolongation: A Prospective Study

NCT04502355 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2020-08-06

No results posted yet for this study

Summary

The antifungal voriconazole is effective for the treatment of invasive fungal infections in immunocompromised patients. A serious adverse reaction is QT interval prolongation, which may precede life-threatening arrhythmias, such as torsades de pointes. Although ventricular arrhythmias are mentioned as a possible adverse effect of voriconazole, thus far, the incidence and clear recommendations for QT follow-up have not been published. This prospective observational study aimed at describing the incidence of voriconazole induced- QT interval prolongation in the pediatric population and determine the risk factors for this phenomenon.

Conditions

  • Voriconazole Induced QT Interval Prolongation

Sponsors & Collaborators

  • Rabin Medical Center

    lead OTHER

Eligibility

Max Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-12-31
Completion
2020-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04502355 on ClinicalTrials.gov